Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | THPO | P40225 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ACE | P12821 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16451649 | 0.86 | MAPT (0.40) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL15700546 | 0.79 | KDM4E (0.34) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL19879921 | 0.73 | — | — | |
| SCHEMBL15033264 | 0.72 | — | — | |
| SCHEMBL9809019 | 0.72 | KDM4E (0.35) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL16688770 | 0.71 | — | — | |
| SCHEMBL19155459 | 0.71 | KDM4E (0.42) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL13261389 | 0.71 | KDM4E (0.42) | KDM4EMAPTTHRBALOX15NFKB1 | |
| Hydrochloric Acid SCHEMBL9809055 | 0.70 | KDM4E (0.34) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL15033316 | 0.70 | KDM4E (0.33) | KDM4EMAPTTHRBALOX15NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067701-A1 | ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME | REGENERON PHARMACEUTICALS, INC. | 2024-02-29 | — | — | US | disclosed |
| US-20230357357-A1 | ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME | REGENERON PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230331812-A1 | ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME | REGENERON PHARMACEUTICALS, INC. | 2023-10-19 | — | — | US | disclosed |
| US-11753459-B2 | Anti-VEGF protein compositions and methods for producing the same | REGENERON PHARMACEUTICALS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20230272044-A1 | ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME | REGENERON PHARMACEUTICALS | 2023-08-31 | — | — | US | disclosed |
| US-11732025-B2 | Anti-VEGF protein compositions and methods for producing the same | REGENERON PHARMACEUTICALS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20230235019-A1 | ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME | REGENERON PHARMACEUTICALS, INC. | 2023-07-27 | — | — | US | disclosed |
| US-11649273-B2 | Anti-VEGF protein compositions and methods for producing the same | REGENERON PHARMACEUTICALS, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-9896715-B2 | Method for analyzing formyl glycine residue | JCR PHARMACEUTICALS CO., LTD. (JP) | 2018-02-20 | — | — | US | disclosed |
| US-20150044715-A1 | METHOD FOR ANALYZING FORMYL GLYCINE RESIDUE | JCR PHARMACEUTICALS CO., LTD. (JP) | 2015-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11649273-B2 | Anti-VEGF protein compositions and methods for producing the same | VEGFA, HDGF, PDGFA | KDM4E 3284/4885MAPT 2868/4885THRB 3962/4885 |
| US-20230235019-A1 | ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME | VEGFA, HDGF, FLT4 | KDM4E 3002/4885MAPT 3067/4885THRB 3902/4885 |
| US-11732025-B2 | Anti-VEGF protein compositions and methods for producing the same | VEGFA, HDGF, PDGFA | KDM4E 3284/4885MAPT 2868/4885THRB 3962/4885 |
| US-20230331812-A1 | ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME | VEGFA, HDGF, PDGFA | KDM4E 3284/4885MAPT 2868/4885THRB 3962/4885 |
| US-11753459-B2 | Anti-VEGF protein compositions and methods for producing the same | VEGFA, HDGF, FLT4 | KDM4E 3002/4885MAPT 3067/4885THRB 3902/4885 |
| US-20230357357-A1 | ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME | VEGFA, HDGF, PDGFA | KDM4E 3284/4885MAPT 2868/4885THRB 3962/4885 |
| US-20230272044-A1 | ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME | VEGFA, HDGF, FLT4 | KDM4E 3002/4885MAPT 3067/4885THRB 3902/4885 |
| US-20240067701-A1 | ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME | VEGFA, HDGF, FLT4 | KDM4E 2754/4885MAPT 2597/4885THRB 1918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.